Stocks · News reference

Ligand Pharmaceuticals Announces Acquisition Of EMEA Royalty On Santen's Pediatric Myopia Drug Ryjunea From Sydnexis For $23M Upfront

Sep 22, 2026, 11:13 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 7, 2026, 8:00 AMBenzinga Insights
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
LGND
BenzingaSep 25, 2026, 12:30 PMBenzinga Newsdesk
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.
LGND
BenzingaSep 24, 2026, 3:54 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
LGND
BenzingaSep 24, 2026, 11:05 AMBenzinga Newsdesk
Ligand Announces Up To $47M Financing For CAR-T Developer AvenCell, Including Up To $41M For Pipeline Royalties
LGND